Compound ID | 1875
Synonym(s): MK-7655
Class: Beta-lactamase inhibitor
| Agent Type: | Synthetic; Small molecule; Direct acting; Antibiotic adjuvant; |
| Mechanism of action: | Binds reversibly to the beta-lactamase in the active site; inhibits class A, C, D beta-lactamases |
| Combined with other compounds: | Yes |
| Description: | Synthetic compound. 2019 approved in fixed combination with imipenem/cilastatin (Recarbrio); a non-beta-lactam beta-lactamase inhibitor, diazabicyclooctane (DBO); no intrinsic antibacterial activity |
| Institute where first reported: | Merck Sharp & Dohme |
| Year first mentioned: | 2009 |
| Highest development stage: | Approved by FDA in 2019 |
| Development status: | Approved |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/44129647 |
| Guide to Pharmacology: | relebactam |
| Citation: | https://www.sciencedirect.com/science/article/abs/pii/S136952741100110X?via%3Dihub |